HRTX

Heron Therapeuti

HRTX, USA

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

https://www.herontx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HRTX
stock
HRTX

Heron Therapeutics Inc (HRTX) can make a big difference with a little luck setenews.com

Read more →
HRTX
stock
HRTX

Aug Rallies: How geopolitical tensions affect ENDRA Life Sciences Inc stock - Profit Target & Weekly High Return Stock Forecasts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$4.5

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

15.56

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-117.53 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.03 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

3.48 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

15.72

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.37% of the total shares of Heron Therapeuti

1.

Rubric Capital Management LP

(17.4266%)

since

2025/06/30

2.

BlackRock Inc

(6.5899%)

since

2025/06/30

3.

Vanguard Group Inc

(5.5264%)

since

2025/06/30

4.

Adage Capital Partners Gp LLC

(5.1223%)

since

2025/06/30

5.

Velan Capital Investment Management LP

(4.5578%)

since

2025/06/30

6.

Palisade Capital Management LLc

(3.3184%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.9896%)

since

2025/07/31

8.

Tejara Capital Ltd

(2.9469%)

since

2025/06/30

9.

iShares Russell 2000 ETF

(2.4402%)

since

2025/08/31

10.

Geode Capital Management, LLC

(2.3268%)

since

2025/06/30

11.

State Street Corp

(2.2586%)

since

2025/06/30

12.

D. E. Shaw & Co LP

(2.0877%)

since

2025/06/30

13.

Palisade Small Cap Core Equity

(2.0815%)

since

2025/06/30

14.

UBS Group AG

(2.0777%)

since

2025/06/30

15.

AIGH Capital Management, LLC

(1.9631%)

since

2025/06/30

16.

Marshall Wace Asset Management Ltd

(1.8879%)

since

2025/06/30

17.

T. Rowe Price Associates, Inc.

(1.8799%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(1.8015%)

since

2025/06/30

19.

Renaissance Technologies Corp

(1.7544%)

since

2025/06/30

20.

JW Asset Management, LLC

(1.525%)

since

2025/06/30

21.

Congress Park Capital LLC

(1.4797%)

since

2025/06/30

22.

Citadel Advisors Llc

(1.4494%)

since

2025/06/30

23.

TANG CAPITAL MANAGEMENT LLC

(1.3931%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0105%)

since

2025/07/31

25.

Fidelity Small Cap Index

(1.0019%)

since

2025/06/30

26.

iShares Russell 2000 Value ETF

(0.7686%)

since

2025/08/31

27.

Fidelity Extended Market Index

(0.4939%)

since

2025/07/31

28.

Vanguard Russell 2000 ETF

(0.4774%)

since

2025/07/31

29.

Bridgeway Ultra-Small Company

(0.4566%)

since

2025/06/30

30.

Schwab US Small-Cap ETFâ„¢

(0.4243%)

since

2025/08/30

31.

State Street Instl Small-Cap Equity Inv

(0.4077%)

since

2025/08/31

32.

Orchard Small Cap Value ESG

(0.3979%)

since

2025/05/31

33.

State St Russell Sm Cap® Indx SL Cl I

(0.3764%)

since

2025/08/31

34.

Orchard US Small Cap Value USD Instl 1

(0.2993%)

since

2025/08/31

35.

Schwab Small Cap Index

(0.2509%)

since

2025/07/31

36.

Vanguard Health Care ETF

(0.2469%)

since

2025/07/31

37.

NT R2000 Index Fund - NL

(0.2415%)

since

2025/06/30

38.

iShares Micro-Cap ETF

(0.2245%)

since

2025/08/31

39.

Extended Equity Market Fund K

(0.2078%)

since

2025/06/30

40.

Goldman Sachs Small Cp Val Insghts Instl

(0.1977%)

since

2025/04/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.0361

EPS Estimate

-0.01

EPS Difference

-0.0261

Surprise Percent

-261%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.